How can I order a blood‑glucose meter and test strips for a Medicare‑eligible patient with diabetes (e.g., on insulin therapy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ordering Glucose Monitors and Test Strips for Medicare Patients

Medicare Part B covers blood glucose meters and test strips as durable medical equipment (DME) when prescribed by a physician for patients with diabetes, particularly those on insulin therapy, and must be obtained through Medicare-approved DME suppliers using proper documentation and billing procedures. 1

Medicare Coverage Requirements

Patient Eligibility Criteria

  • Medicare Part B covers glucose monitoring supplies for beneficiaries with diabetes who meet specific clinical criteria. 1
  • Patients on insulin therapy have the strongest indication for coverage, as blood glucose monitoring is integral to safe insulin management and hypoglycemia prevention. 2, 3
  • Coverage extends to patients on multiple daily injections or insulin pump therapy who require testing 6-10 times daily depending on individual needs. 2

Required Documentation

  • A physician's written order (prescription) is mandatory before DME suppliers can dispense glucose meters and test strips. 1
  • The prescription must document the diabetes diagnosis and specify the medical necessity for glucose monitoring. 1
  • For insulin-treated patients, documentation should note the insulin regimen (basal, bolus, or both) to justify testing frequency. 2, 3

Ordering Process

Step 1: Write the Prescription

  • Prescribe an FDA-approved glucose meter with proven accuracy, specifying the quantity of test strips based on the patient's insulin regimen. 3, 4
  • For patients on intensive insulin therapy (multiple daily injections or pump), prescribe sufficient strips for testing before meals and snacks, at bedtime, before exercise, when hypoglycemia is suspected, and before critical tasks like driving—typically 6-10 tests daily. 2, 3
  • Include lancets in the prescription, as they are covered alongside test strips. 1
  • Specify that strips must be unexpired and purchased from a pharmacy or licensed distributor. 3, 4

Step 2: Direct Patient to Medicare-Approved DME Supplier

  • Patients must obtain supplies through Medicare-enrolled DME suppliers who have been approved by Medicare administrative contractors. 1
  • Verify the supplier's Medicare enrollment status, as only approved suppliers can bill Medicare Part B for diabetes testing supplies. 1
  • Many chain pharmacies are Medicare-approved DME suppliers and can process these orders. 1

Step 3: Supplier Responsibilities

  • The DME supplier will verify Medicare eligibility and obtain the physician's written order before dispensing supplies. 1
  • Suppliers must maintain documentation of medical necessity and comply with national and local coverage requirements. 1
  • The supplier bills Medicare Part B directly for covered supplies. 1

Testing Frequency Guidelines by Treatment Regimen

Intensive Insulin Therapy (Multiple Daily Injections or Pump)

  • Prescribe strips for 6-10 tests daily: before meals and snacks, at bedtime, occasionally postprandially, before exercise, when hypoglycemia is suspected, after treating hypoglycemia until normoglycemic, and before critical tasks. 2, 3

Basal Insulin Only or Non-Insulin Therapy

  • Testing frequency should be lower and individualized, as routine glucose monitoring in non-insulin-treated patients has limited clinical benefit unless used to adjust therapy. 3, 5
  • Consider prescribing strips for fasting glucose checks and periodic postprandial testing when modifying meal plans, physical activity, or medications. 3, 4

Critical Pitfalls to Avoid

Accuracy and Safety Issues

  • Never prescribe non-FDA-approved meters, as accuracy varies significantly between devices and only FDA-approved meters should be used. 3, 4
  • Warn patients against purchasing preowned or secondhand test strips, as these may give incorrect results and compromise safety. 4
  • Ensure patients understand that only unopened, unexpired strips from licensed distributors should be used. 4

Billing and Compliance Concerns

  • Be aware that diabetes testing supplies are subject to extensive Medicare audits due to concerns about improper billing. 1
  • Ensure medical necessity is clearly documented to avoid prepayment review or postpayment audits. 1
  • Do not order excessive quantities that exceed clinical need, as this triggers Medicare contractor scrutiny. 1

Clinical Considerations

  • Patients using continuous glucose monitoring (CGM) must still have access to blood glucose meters at all times for calibration (if required by device) and backup testing. 4, 6
  • Provide education on proper meter use, as performing blood glucose monitoring alone does not lower glucose levels—the information must be integrated into self-management plans. 2, 5
  • Reevaluate the ongoing need and frequency of testing at each routine visit to avoid overuse, particularly if monitoring is not being used effectively for self-management. 2

Alternative: Pharmacy Benefit Coverage

  • Some state Medicaid programs and insurers have transitioned CGM coverage from DME to pharmacy benefit, which improves access and reduces administrative burden. 7
  • For Medicare patients, traditional glucose meters and strips remain under Part B DME coverage, but this landscape may evolve. 1, 7

References

Related Questions

For a 19‑year‑old with type 1 diabetes, weight 86 kg, creatinine 0.74 mg/dL, GFR > 90 mL/min, bicarbonate 17 mmol/L, anion gap 13, currently on metformin 750 mg daily and insulin glargine (Lantus) 15 U at 8 am and 35 U at 8 pm with carbohydrate‑to‑insulin ratios of 1 U per 6 g carbs at breakfast and 1 U per 7 g carbs at lunch/dinner and an insulin‑sensitivity factor of 25 mg/dL per U, and blood glucose values of 184 mg/dL (8 am), 220 mg/dL (noon), 262 mg/dL (5 pm), 237 mg/dL (10 pm), and 97 mg/dL (4 am), what should the morning and evening Lantus doses be and what should the insulin‑sensitivity factor and insulin‑to‑carbohydrate ratios be adjusted to?
What does a basal insulin level of 2.3 (microunits per milliliter) indicate in a 48-year-old man with no known diabetes?
In a 27‑year‑old woman with type 2 diabetes, weight 86.6 kg, creatinine 0.40 mg/dL, GFR > 90 mL/min, currently taking neutral protamine Hagedorn (NPH) insulin 32 U at 8 am, dexamethasone 20 mg daily, with an insulin‑to‑carbohydrate ratio (ICR) of 1 U per 3 g carbohydrate and an insulin sensitivity factor (ISF) of 25 mg/dL per U, and blood glucose values of 207 mg/dL at 9 am, 229 mg/dL after a 90‑g carbohydrate meal, 373 mg/dL at 5 pm, 340 mg/dL at 9 pm, and 286 mg/dL at 2 am, what should the NPH basal insulin dose, ISF, and ICR be adjusted to?
A 28‑week‑gestation pregnant woman weighing 114 kg has a fasting blood glucose of 157 mg/dL while on insulin glargine (Lantus) 40 units daily; how much should the insulin glargine dose be increased?
How should a 19‑year‑old female with a family history of diabetes, normal fasting glucose (88 mg/dL) and HbA1c (5.2 %), but elevated fasting insulin (47.3 µU/mL) be managed?
How can I unblock a nephrostomy tube that is not draining urine despite proper placement?
What is the expected weight gain rate for a healthy, full‑term 4‑month‑old infant receiving adequate breast milk or formula?
In a patient with anemia and a low serum lactate dehydrogenase (LDH) level, what is the clinical significance and how should the anemia be evaluated?
Can ciprofloxacin be used to treat acute otitis media or chronic suppurative otitis media, particularly in patients with a beta‑lactam allergy or a perforated tympanic membrane?
What is pseudo‑progression in a patient receiving immune‑checkpoint inhibitor therapy who shows radiologic tumor growth but remains clinically stable (no new symptoms, stable performance status, and no laboratory evidence of disease acceleration)?
How should I manage a patient taking valsartan 80 mg once daily with uncontrolled blood pressure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.